Bristol-Myers Squibb buys Celgene

The drugmaker merger is worth $74 billion.

Bottles of medicine Source: Bloomberg

Drugmaker Bristol-Myers has bought biotech company Celgene in a blockbuster $74 billion deal. The merger is the largest in the history of pharmaceuticals. The purchase has led to a surge in shares in both corporations.

Why Bristol- Myers bought Celgene

Bristol-Myers is the most dominant drugmaker in the US, but has faced competition from other pharmaceutical corporations like Merck in cancer fighting medication. Celgene is a biotech company that is working on gene therapy this is supposed to attack cancer cells. The merger is supposed to help the companies work together to create groundbreaking treatment for life-threatening illnesses. Bristol-Myers chief executive officer(CEO), Giovanni Cafario, noted the importance of the merger in a statement.

‘Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,’ noted Cafario.

‘Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,’ noted Cafario.

The merger will greatly benefit Celgene because its stock had been suffering in 2018. The company’s shares fell 40% even after billion-dollar purchases of other biotech corporations. Bristol-Myers stock suffered last year when the US Food and Drug Administration (FDA) delayed approval of two of its medications. Brad Loncar, chief executive officer(CEO) of Loncar Investments, noted that the joint venture was necessary for both companies to overcome poor business decisions.

‘Both of them were coming into this year kind of limping. Merging together makes the combined entity a lot stronger,’ said Loncar.

Details of the merger

Under the deal, Celgene shareholders will get $102.43 per Bristol-Myers share. They will also own 31% of the company, while Bristol-Myers stock purchasers will have control of 69% of the combined corporation. The merger is expected to be completed by the third quarter (Q3) of2019.

See an opportunity to trade?

Go long or short on more than 15,000 markets with IG.

Spread bet or trade CFDs on our award-winning platform, with low spreads on indices, shares, commodities and more.

Related articles

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Bid
Offer
Updated
Change
Bid
Offer
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.


This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 81% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.